What is Enveric Biosciences, Inc.'s earnings per share (EPS)?

Enveric Biosciences, Inc. (ENVB) reported diluted earnings per share of -$36.24 for fiscal year 2025. This represents a 84.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Enveric Biosciences, Inc. (ENVB) Financials

ENVB

FY2025 annual

Revenue Not reported for FY2025

Net Income $12.1M +26.0% YoY

EPS (Diluted) -$36.24 +84.1% YoY

Operating Cash Flow -$8.1M -5.4% YoY

Market Cap $6.5M as of Oct 10, 2026

Price / Sales n/m no revenue reported

Price / Earnings 0.5x on $12.1M net income, FY2025

Price / Book 0.8x on $8.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENVB SEC filings page.

This page shows Enveric Biosciences, Inc. (ENVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENVB FY2025 2026-10-03

Reported profits are not coming from operations: the business remains cash-consuming while external financing supports its balance sheet.

Earnings quality is weak: from FY2023 through FY2025, net income stayed positive while operating income and operating cash flow remained negative. That divergence indicates that reported profits were driven by items outside the core operating activity, not by cash-generating operations.

FY2025 SG&A fell to $5.8M while R&D was $2.8M, bringing the reported cost base below FY2024 levels. But operating cash flow worsened from -$7.7M to -$8.1M even as the operating loss narrowed, so lower reported expenses have not improved cash conversion.

Liabilities fell from $1.5M to $918K, improving the balance-sheet cushion. However, $10.6M of financing inflows accompanied $8.1M of operating cash outflow, indicating that the reported strengthening came from external funding rather than internally generated cash.

Financial Health Signals

Financial health score not available

Enveric Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Enveric Biosciences, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$0.67used

For every $1 of reported earnings, Enveric Biosciences, Inc. used $0.67 of operating cash (-$8.1M OCF vs $12.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

Enveric Biosciences, Inc. reported an operating loss of $8.8M against $106 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$3.0M

YoY-20.6%

QoQ-87.4%

Enveric Biosciences, Inc.'s EBITDA was -$3.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.6% from the same quarter a year earlier. Against the prior quarter it is down 87.4%.

Net Income

-$3.0M

YoY-20.2%

QoQ-85.4%

Enveric Biosciences, Inc. reported -$3.0M in net income in Q2 2026. This represents a decrease of 20.2% from the same quarter a year earlier. Against the prior quarter it is down 85.4%.

EPS (Diluted)

-$0.76

Enveric Biosciences, Inc. earned -$0.76 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$8.3M

YoY+191.1%

QoQ+69.0%

5Y CAGR-16.6%

Enveric Biosciences, Inc. held $8.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

5Y CAGR-26.9%

10Y CAGR-10.4%

Enveric Biosciences, Inc. had 4M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-37.5%

YoY+77.8pp

QoQ-5.2pp

Enveric Biosciences, Inc.'s ROE was -37.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 77.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.4M

YoY+7.5%

QoQ+291.7%

Enveric Biosciences, Inc. invested $1.4M in research and development in Q2 2026. This represents an increase of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 291.7%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

ENVB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENVB quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1510-K	FY1410-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$43.0M-11.5%	$48.6M+34.4%	$36.1M+78.4%	$20.3M	$16.8M+173.5%	$6.1M	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$34.0M-11.3%	$38.4M+31.3%	$29.2M+118.2%	$13.4M	$15.1M+188.8%	$5.2M	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$9.0M-12.3%	$10.2M+47.8%	$6.9M+0.9%	$6.9M	$1.7M+85.5%	$911K	N/A	N/A
R&D Expenses	N/A	$2.8M-2.1%	$2.8M-60.8%	$7.3M-9.7%	$8.0M+67.6%	$4.8M+2650.9%	$174K	N/A	N/A	N/A	$55K	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$5.8M-10.2%	$6.5M-27.1%	$8.9M-23.7%	$11.6M-43.4%	$20.5M+285.1%	$5.3M	N/A	$10.8M-41.7%	$18.5M+97.7%	$9.4M+63.6%	$5.7M	-$33K-20.6%	-$27K	$23K-27.7%	$31K
Operating Income	N/A	-$8.8M+8.9%	-$9.6M+41.4%	-$16.4M+40.0%	-$27.4M+57.6%	-$64.6M-1050.4%	-$5.6M	N/A	-$7.1M+34.4%	-$10.9M-102.5%	-$5.4M-577.6%	-$794K	$33K+20.6%	$27K	-$23K+27.7%	-$31K
EBITDA	N/A	-$8.6M+7.8%	-$9.3M+42.3%	-$16.1M+40.5%	-$27.1M+57.7%	-$64.0M-1063.8%	-$5.5M-17495.9%	-$31K+99.3%	-$4.2M+44.8%	-$7.7M-91.1%	-$4.0M-540.1%	-$628K	$66K+142.2%	$27K	N/A	N/A
Interest Expense	N/A	-$106-148.4%	$219-94.1%	$4K-29.4%	$5K-49.1%	$10K-97.7%	$445K+444.2%	$82K-88.8%	$730K+26.9%	$575K-23.4%	$751K+215.0%	$238K	N/A	$15	N/A	N/A
Income Tax	N/A	N/A	$9K-69.1%	$29K+101.9%	-$1.5M+80.1%	-$7.5M	N/A	$389K-93.9%	$6.3M+365.4%	-$2.4M+36.2%	-$3.7M-2817.5%	-$128K	$833-42.6%	$1K	$2K-2.7%	$2K
Net Income	N/A	$12.1M+26.0%	$9.6M-45.1%	$17.5M+194.7%	-$18.5M+62.3%	-$49.0M-613.5%	-$6.9M	N/A	-$16.9M-86.2%	-$9.1M-226.4%	-$2.8M-241.6%	-$814K	-$34K-20796.9%	-$161	-$25K+26.2%	-$33K
EPS (Basic)	N/A	-$36.24+84.1%	-$228.48-88.4%	-$121.29-833.0%	-$13.00+87.5%	-$103.69	N/A	-$2.83+86.2%	-$20.47-2629.3%	-$0.75-257.1%	-$0.21-200.0%	-$0.07	$4.27-32.5%	$6.33	N/A	N/A
EPS (Diluted)	—	-$36.24+84.1%	-$228.48	-$121.29	-$13.00	N/A	N/A	-$2.83	-$20.47	-$0.75-257.1%	-$0.21-200.0%	-$0.07	$4.27-32.5%	$6.33	N/A	N/A
Diluted Shares (Avg)	N/A	334,719+698.7%	41,908	143,938	1M	N/A	N/A	2M	951,601	15M+14.6%	13M+17.7%	11M	99,225+51.5%	65,509	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.4M+7.5%	$346K-53.6%	N/A	$402K-49.9%	$1.3M+123.0%	$746K+47.5%	N/A	$803K-37.4%
SG&A Expenses	$1.6M+34.2%	$1.2M-8.1%	N/A	$1.4M+19.7%	$1.2M-2.3%	$1.4M-27.9%	N/A	$1.2M-42.5%
Operating Income	-$3.0M-20.2%	-$1.6M+25.3%	N/A	-$1.9M+10.0%	-$2.5M-32.7%	-$2.2M+11.7%	N/A	-$2.1M+39.6%
EBITDA	-$3.0M-20.6%	-$1.6M+24.2%	N/A	-$1.8M+8.2%	-$2.5M-36.7%	-$2.1M+11.9%	N/A	-$2.0M+40.6%
Interest Expense	-$292-121.2%	-$303-15250.0%	N/A	$274+226.3%	-$132-277.1%	$2-99.7%	N/A	-$217-109.7%
Net Income	-$3.0M-20.2%	-$1.6M+25.2%	N/A	-$1.9M+10.1%	-$2.5M-34.0%	-$2.2M+11.1%	N/A	-$2.1M+26.2%
EPS (Basic)	-$0.76+93.5%	-$1.08+92.6%	-$0.50+99.1%	-$10.81+74.9%	-$11.65-213.2%	-$14.58-58.3%	-$57.81-3832.7%	-$43.10-3215.4%
EPS (Diluted)	-$0.76	-$1.08	-$0.50+99.1%	-$10.81	-$11.65	-$14.58	-$57.81	-$43.10
Diluted Shares (Avg)	4M	2M	N/A	313,242	216,311	149,815	N/A	48,350

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

ENVB Balance Sheet

ENVB quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1510-K	FY1410-K	FY1210-K	FY1110-K
Total Assets	$5.1M+65.3%	$3.1M-28.3%	$4.3M-78.0%	$19.6M-26.8%	$26.7M+552.2%	$4.1M+3665.9%	$109K-99.6%	$29.6M-43.2%	$52.2M+32.1%	$39.5M+185.6%	$13.8M	$4.5M+29.7%	$3.4M	$6K-75.1%	$22K
Current Assets	$4.9M+80.5%	$2.7M-23.6%	$3.6M-80.6%	$18.4M+3.9%	$17.7M+678.2%	$2.3M+1995.0%	$109K-98.9%	$10.1M-31.3%	$14.6M+45.5%	$10.1M+40.2%	$7.2M	$4.3M+26.0%	$3.4M	$6K-75.1%	$22K
Cash & Equivalents	$4.7M+108.7%	$2.2M-2.1%	$2.3M-87.1%	$17.7M+2.1%	$17.4M+999.6%	$1.6M	N/A	$1.4M-71.9%	$4.9M+253.8%	$1.4M-26.5%	$1.9M	$826K+120.3%	$375K	$1K-92.4%	$18K
Short-Term Investments	$0	$0	$0	$0	$0	$0	N/A	$0	$0-100.0%	$83K	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$7.9M-10.9%	$8.8M+9.7%	$8.1M+65.4%	$4.9M	$3.0M+1.5%	$2.9M	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$380K-76.1%	$1.6M	N/A	N/A	$13.7M-37.3%	$21.9M+28.1%	$17.1M+392.4%	$3.5M	N/A	N/A	N/A	N/A
Total Liabilities	$918K-38.4%	$1.5M-36.4%	$2.3M-41.4%	$4.0M-9.5%	$4.4M+547.8%	$681K-64.5%	$1.9M-93.5%	$29.7M-9.3%	$32.7M+17.6%	$27.8M+105.1%	$13.6M	$3.5M+15.7%	$3.0M	$26K+43.4%	$18K
Current Liabilities	$918K-38.4%	$1.5M-36.4%	$2.3M-41.4%	$4.0M+46.0%	$2.7M+301.8%	$681K	N/A	$14.7M-51.6%	$30.4M+138.9%	$12.7M+48.2%	$8.6M	$3.5M+15.7%	$3.0M	$26K+43.4%	$18K
Non-Current Liabilities	$0	$0	$0	$0-100.0%	$1.7M	$0-100.0%	$1.2M-72.1%	$4.2M+76.0%	$2.4M-84.3%	$15.1M+202.7%	$5.0M	$0	$0	$0	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$740K	$0-100.0%	$1.1M-26.4%	$1.5M-69.3%	$5.0M	N/A	N/A	N/A	N/A
Total Equity	$4.2M+162.3%	$1.6M-18.6%	$2.0M-86.7%	$14.7M-34.2%	$22.3M+553.1%	$3.4M+288.5%	-$1.8M-2667.7%	-$65K-100.3%	$19.4M+66.7%	$11.7M+4411.5%	$259K	$973K+129.1%	$425K	-$20K-540.5%	$5K
Retained Earnings	-$114.8M-8.3%	-$106.1M-9.9%	-$96.5M-21.8%	-$79.2M-30.4%	-$60.7M-416.5%	-$11.8M-140.2%	-$4.9M+85.8%	-$34.5M-129.9%	-$15.0M-291.2%	-$3.8M-264.1%	-$1.1M	$838K+102.1%	$415K	-$47.4M-0.1%	-$47.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$8.9M+152.1%	$5.5M+8.2%	$5.1M+65.3%	$4.4M-8.9%	$3.5M-41.4%	$5.1M-42.3%	$3.1M-28.3%	$4.8M-27.6%
Current Assets	$8.8M+165.9%	$5.4M+11.2%	$4.9M+80.5%	$4.2M-4.0%	$3.3M-40.1%	$4.8M-41.2%	$2.7M-23.6%	$4.3M-25.5%
Cash & Equivalents	$8.3M+191.1%	$4.9M+14.3%	$4.7M+108.7%	$3.8M+20.8%	$2.8M-18.6%	$4.3M-32.4%	$2.2M-2.1%	$3.1M-27.1%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$861K-36.8%	$461K-61.1%	$918K-38.4%	$906K+8.0%	$1.4M+111.3%	$1.2M-50.0%	$1.5M-36.4%	$839K-79.9%
Current Liabilities	$861K-36.8%	$461K-61.1%	$918K-38.4%	$906K+8.0%	$1.4M+111.3%	$1.2M-50.0%	$1.5M-36.4%	$839K-79.9%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	$8.1M+269.9%	$5.1M+29.2%	$4.2M+162.3%	$3.5M-12.5%	$2.2M-59.6%	$3.9M-39.6%	$1.6M-18.6%	$4.0M+62.2%
Retained Earnings	-$119.5M-7.9%	-$116.5M-7.6%	-$114.8M-8.3%	-$112.7M-9.5%	-$110.8M-9.9%	-$108.3M-9.4%	-$106.1M-9.9%	-$102.9M-10.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ENVB Cash Flow Statement

ENVB quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1510-K	FY1410-K	FY1210-K	FY1110-K
Operating Cash Flow	-$8.6M	-$8.1M-5.4%	-$7.7M+45.2%	-$14.1M+17.8%	-$17.1M-49.7%	-$11.5M-194.6%	-$3.9M	N/A	-$2.6M+6.4%	-$2.7M-1.4%	-$2.7M+30.7%	-$3.9M	-$43K-99.5%	-$22K	-$25K+18.1%	-$30K
Depreciation & Amortization	N/A	$201K-40.5%	$337K-1.9%	$344K+4.9%	$328K-50.1%	$657K+443.3%	$121K	N/A	$2.9M-9.7%	$3.2M+136.4%	$1.4M+719.0%	$166K	$33K+28669.0%	$116	N/A	N/A
Stock-Based Compensation	N/A	$827K-47.0%	$1.6M-27.3%	$2.2M-18.0%	$2.6M-79.2%	$12.6M+537.1%	$2.0M+216.8%	$624K+4.0%	$600K-91.5%	$7.1M+385.6%	$1.5M	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	$5K-99.1%	$584K+207.9%	$190K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$14.1M+20.5%	-$17.7M-52.2%	-$11.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$12K+102.0%	-$584K-126.7%	$2.2M+5062.5%	-$44K+84.5%	-$284K+92.2%	-$3.6M-2042.5%	-$170K+97.4%	-$6.6M-259.0%	-$1.8M	-$500K-15531.1%	-$3K	N/A	N/A
Financing Cash Flow	$14.0M	$10.6M+37.9%	$7.7M+671.3%	-$1.3M-107.4%	$18.2M-27.0%	$24.9M+350.2%	$5.5M	N/A	$2.7M-58.0%	$6.4M-27.1%	$8.8M+41.1%	$6.2M	$48K+134.1%	$21K	$8K-83.1%	$47K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.4M-29.3%	-$2.3M+5.6%	-$1.8M-36.1%	-$2.1M-123.8%	-$1.9M+34.6%	-$2.4M+8.0%	-$1.3M+25.1%	-$927K+66.2%
Depreciation & Amortization	$37K-7.9%	$37K-54.0%	$39K-52.1%	$40K-52.4%	$40K-52.8%	$81K-5.1%	$82K-2.6%	$85K-1.7%
Stock-Based Compensation	N/A	$89K-54.3%	N/A	$187K-49.5%	$206K-44.2%	$194K-44.8%	N/A	$369K+12.5%
Financing Cash Flow	$5.8M+1201.5%	$2.5M-43.7%	$2.7M+480.2%	$3.0M+478.0%	$449K+1204.4%	$4.4M-33.2%	$463K+349.1%	$518K+593.0%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

ENVB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENVB quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1510-K	FY1410-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	20.9%-0.2pp	21.1%+1.9pp	19.2%-14.7pp	33.9%	10.1%-4.8pp	14.8%	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-16.6%+5.8pp	-22.4%-7.5pp	-14.9%-11.0pp	-3.9%	0.2%-0.2pp	0.4%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-39.3%-20.6pp	-18.7%-11.0pp	-7.7%-3.7pp	-4.0%	-0.2%-0.2pp	0.0%	N/A	N/A
Return on Equity	289.6%-313.1pp	602.7%-291.8pp	894.5%+1020.4pp	-125.9%+93.7pp	-219.6%-18.6pp	-201.0%	N/A	N/A	-46.7%-22.8pp	-23.8%+291.0pp	-314.9%	-3.5%-3.4pp	0.0%	N/A	-732.8%
Return on Assets	237.4%-74.0pp	311.4%-95.6pp	407.0%+501.5pp	-94.5%+88.8pp	-183.3%-15.7pp	-167.6%	N/A	-57.0%-39.6pp	-17.4%-10.3pp	-7.0%-1.2pp	-5.9%	-0.8%-0.8pp	0.0%	-439.7%-291.0pp	-148.7%
Current Ratio	5.38+3.5x	1.84+0.3x	1.53-3.1x	4.61-1.9x	6.48+3.1x	3.35	N/A	0.69+0.2x	0.48-0.3x	0.790.0x	0.84	1.24+0.1x	1.14	0.22-1.0x	1.25
Debt-to-Equity	0.22-0.7x	0.94-0.3x	1.20+0.9x	0.27+0.1x	0.200.0x	0.20	N/A	N/A	0.06-0.1x	0.13-19.2x	19.34	3.59-3.5x	7.10	N/A	3.93
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	1.45+0.5x	0.930.0x	0.91-0.5x	1.46	3.77+2.0x	1.79	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-37.5%+77.8pp	-32.3%+23.5pp	N/A	-54.2%-1.5pp	-115.3%-80.5pp	-55.8%-17.9pp	N/A	-52.7%+63.1pp
Return on Assets	-33.9%+37.1pp	-29.6%+13.2pp	N/A	-43.0%+0.6pp	-71.0%-39.9pp	-42.8%-15.1pp	N/A	-43.5%-0.9pp
Current Ratio	10.21+7.8x	11.67+7.6x	5.38+3.5x	4.60-0.6x	2.43-6.1x	4.08+0.6x	1.84+0.3x	5.17+3.8x
Debt-to-Equity	0.11-0.5x	0.09-0.2x	0.22-0.7x	0.260.0x	0.62+0.5x	0.30-0.1x	0.94-0.3x	0.21-1.5x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Enveric Biosciences, Inc. ENVB	FY2025	N/A	$12.1M	N/A	$6.5M	—
Indaptus Therapeutics, Inc. INDP	FY2025	N/A	-$20.8M	N/A	$334.4M	—
Qualigen Therapeutics, Inc. QLGN	FY2025	N/A	-$17.0M	N/A	$6.5M	—
Revelation Biosciences, Inc. REVB	FY2025	N/A	-$8.9M	N/A	$3.0M	—
PROTAGENIC THERAPEUTICS PTIX	FY2026	$0	$1.4M	N/A	$1.4M	—

Where Enveric Biosciences, Inc. Ranks

Frequently Asked Questions

Is Enveric Biosciences, Inc. profitable?

Yes, Enveric Biosciences, Inc. (ENVB) reported a net income of $12.1M in fiscal year 2025.

What is Enveric Biosciences, Inc.'s EBITDA?

Enveric Biosciences, Inc. (ENVB) had EBITDA of -$8.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Enveric Biosciences, Inc.'s return on equity (ROE)?

Enveric Biosciences, Inc. (ENVB) has a return on equity of 289.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Enveric Biosciences, Inc.'s operating cash flow?

Enveric Biosciences, Inc. (ENVB) recorded an outflow of $8.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Enveric Biosciences, Inc.'s total assets?

Enveric Biosciences, Inc. (ENVB) had $5.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Enveric Biosciences, Inc. spend on research and development?

Enveric Biosciences, Inc. (ENVB) invested $2.8M in research and development during fiscal year 2025.

How many shares does Enveric Biosciences, Inc. have outstanding?

Enveric Biosciences, Inc. (ENVB) had 2M shares outstanding as of fiscal year 2025.

What is Enveric Biosciences, Inc.'s current ratio?

Enveric Biosciences, Inc. (ENVB) had a current ratio of 5.38 as of fiscal year 2025, which is generally considered healthy.

What is Enveric Biosciences, Inc.'s debt-to-equity ratio?

Enveric Biosciences, Inc. (ENVB) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enveric Biosciences, Inc.'s return on assets (ROA)?

Enveric Biosciences, Inc. (ENVB) had a return on assets of 237.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Enveric Biosciences, Inc.'s P/E ratio?

Enveric Biosciences, Inc. (ENVB) trades at 0.5x earnings, its market capitalization divided by net income of $12.1M net income, FY2025. The market capitalization is $6.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Enveric Biosciences, Inc.'s price-to-sales ratio?

Enveric Biosciences, Inc. (ENVB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $6.5M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Enveric Biosciences, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Enveric Biosciences, Inc. (ENVB) held $4.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Enveric Biosciences, Inc.'s Piotroski F-Score?

Enveric Biosciences, Inc. (ENVB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enveric Biosciences, Inc.'s earnings high quality?

For every $1 of reported earnings, Enveric Biosciences, Inc. (ENVB) used $0.67 of operating cash (-$8.1M OCF vs $12.1M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Enveric Biosciences, Inc. cover its interest payments?

Enveric Biosciences, Inc. (ENVB) reported an operating loss of $8.8M against $106 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.